navtemadlin

Navtemadlin is an orally available, selective small molecule inhibitor of MDM2 (murine double minute 2), developed as an antineoplastic agent. By binding to MDM2, navtemadlin prevents its interaction with the tumor suppressor protein p53, thereby restoring p53’s transcriptional activity and leading to apoptosis in tumor cells with wild-type TP53. This mechanism targets cancers where MDM2 is overexpressed and the p53 pathway is intact. Navtemadlin has shown efficacy in preclinical models by inducing cell cycle arrest and apoptosis, particularly in myelofibrosis and other hematologic malignancies. It is being developed for several indications including myelofibrosis (Phase III), endometrial cancer (Phase II/III), polycythemia vera (Phase II), small cell lung cancer (Phase II), acute myeloid leukemia, chronic lymphocytic leukemia, diffuse large B-cell lymphoma, malignant melanoma, Merkel cell carcinoma, among others.

Brand names

navtemadlin

Other names

navtemadlin